Aarti Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2025
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Drugs Limited held its 40th Annual General Meeting on September 24, 2025, via video conferencing, attended by 99 members. Chairman Prakash M. Patil (MD & CEO) and Chairman Emeritus Chandrakant V. Gogri were present, along with the full Board, auditors, and scrutinizers. Five resolutions were tabled: adoption of audited financial statements for FY ending March 31, 2025, re-appointment of director Harshit Manilal Savla (rotational retiree), revision in remuneration terms of Executive Directors, appointment of a Secretarial Auditor for 5 years, and ratification of Cost Auditors' remuneration for FY 2025-26. The CFO presented financial highlights for FY25 and Q1 FY26 (quarter ended June 30, 2025). Remote e-voting ran September 21–23, 2025, and results will be declared within 2 working days.
This is a routine procedural disclosure with no immediate price-moving impact. Investors should watch for the e-voting results (due within 2 working days) to see shareholder approval levels, particularly on the executive director remuneration revision. Any unusually high dissent on special business items could be a flag worth monitoring.